Loading...

Supernus Pharmaceuticals, Inc.

SUPN•NASDAQ
Healthcare
Drug Manufacturers - Specialty & Generic
$49.76
$-0.63(-1.25%)
U.S. Market opens in NaNh NaNm

Supernus Pharmaceuticals, Inc. (SUPN) Stock Overview

Explore Supernus Pharmaceuticals, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

Z

Key Financials

Market Cap2.9B
P/E Ratio-73.23
EPS (TTM)$-0.68
ROE-0.04%
Fundamental Analysis

AI Price Forecasts

1 Month$53.52
3 Months$50.06
1 Year Target$58.36

SUPN Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Supernus Pharmaceuticals, Inc. (SUPN) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 45.38, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $58.36.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -73.23 and a market capitalization of 2.9B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
-1.25%
5-Day Change
-0.04%
1-Month Change
0.77%
3-Month Change
3.13%
6-Month Change
-5.81%
Year-to-Date (YTD) Change
0.12%
1-Year Change
58.72%
3-Year Change
31.95%
5-Year Change
56.04%
All-Time (Max) Change
826.63%

Contact Information

https://www.supernus.com
301 838 2500
9715 Key West Avenue, Rockville, MD, 20850

Company Facts

674 Employees
IPO DateMay 1, 2012
CountryUS
Actively Trading

Frequently Asked Questions